Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Consolidated Net Income: 2011-2025

Historic Consolidated Net Income for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$35.6 million.

  • Abeona Therapeutics' Consolidated Net Income fell 17.47% to -$35.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$86.1 million, marking a year-over-year increase of 4.84%. This contributed to the annual value of -$68.4 million for FY2024, which is 43.88% down from last year.
  • Per Abeona Therapeutics' latest filing, its Consolidated Net Income stood at -$35.6 million for Q3 2025, which was down 195.60% from -$12.0 million recorded in Q2 2025.
  • Abeona Therapeutics' Consolidated Net Income's 5-year high stood at -$8.2 million during Q2 2022, with a 5-year trough of -$46.7 million in Q4 2021.
  • In the last 3 years, Abeona Therapeutics' Consolidated Net Income had a median value of -$15.3 million in 2024 and averaged -$19.2 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first surged by 71.90% in 2022, then tumbled by 196.31% in 2024.
  • Abeona Therapeutics' Consolidated Net Income (Quarterly) stood at -$46.7 million in 2021, then soared by 71.90% to -$13.1 million in 2022, then fell by 1.56% to -$13.3 million in 2023, then crashed by 33.31% to -$17.8 million in 2024, then fell by 17.47% to -$35.6 million in 2025.
  • Its Consolidated Net Income was -$35.6 million in Q3 2025, compared to -$12.0 million in Q2 2025 and -$20.7 million in Q1 2025.